BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 29563117)

  • 1. Platelet Signaling Pathways and New Inhibitors.
    Grover SP; Bergmeier W; Mackman N
    Arterioscler Thromb Vasc Biol; 2018 Apr; 38(4):e28-e35. PubMed ID: 29563117
    [No Abstract]   [Full Text] [Related]  

  • 2. Platelet Function in Cardiovascular Disease: Activation of Molecules and Activation by Molecules.
    Khodadi E
    Cardiovasc Toxicol; 2020 Feb; 20(1):1-10. PubMed ID: 31784932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Antiplatelet Agents in Cardiovascular Disease.
    Tscharre M; Michelson AD; Gremmel T
    J Cardiovasc Pharmacol Ther; 2020 May; 25(3):191-200. PubMed ID: 31960728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological inhibition of platelet reactivity. Clinical and pharmacodynamic effects.
    Vallés J; Moscardo A; Madrid I; Santos MT
    Curr Vasc Pharmacol; 2013 Jul; 11(4):431-47. PubMed ID: 23905638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting glycoprotein VI and the immunoreceptor tyrosine-based activation motif signaling pathway.
    Stegner D; Haining EJ; Nieswandt B
    Arterioscler Thromb Vasc Biol; 2014 Aug; 34(8):1615-20. PubMed ID: 24925975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Editorial: Paving the way for improved antiplatelet therapy.
    Grove EL
    Curr Pharm Des; 2012; 18(33):5195-6. PubMed ID: 22724421
    [No Abstract]   [Full Text] [Related]  

  • 7. Platelet Signaling and Disease: Targeted Therapy for Thrombosis and Other Related Diseases.
    Yeung J; Li W; Holinstat M
    Pharmacol Rev; 2018 Jul; 70(3):526-548. PubMed ID: 29925522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Future innovations in anti-platelet therapies.
    Barrett NE; Holbrook L; Jones S; Kaiser WJ; Moraes LA; Rana R; Sage T; Stanley RG; Tucker KL; Wright B; Gibbins JM
    Br J Pharmacol; 2008 Jul; 154(5):918-39. PubMed ID: 18587441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retinal vein occlusion disease and platelet activation: will antiplatelet therapy be a promising therapeutic strategy for patients with retinal vein occlusion disease in the future?
    Fateh-Moghadam S; Gawaz M
    Thromb Haemost; 2007 Feb; 97(2):169-70. PubMed ID: 17264941
    [No Abstract]   [Full Text] [Related]  

  • 10. Receptor-mediated inhibitory mechanisms and the regulation of platelet function.
    Cheng Z; Liu J
    Sci China Life Sci; 2015 Dec; 58(12):1299-301. PubMed ID: 26588910
    [No Abstract]   [Full Text] [Related]  

  • 11. Antiplatelet activity of drugs used in hypertension, dyslipidemia and diabetes: Additional benefit in cardiovascular diseases prevention.
    Sepúlveda C; Palomo I; Fuentes E
    Vascul Pharmacol; 2017 Apr; 91():10-17. PubMed ID: 28342822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology of platelet activation-inhibitory drugs.
    Rao GH; Rao AT
    Indian J Physiol Pharmacol; 1994 Apr; 38(2):69-84. PubMed ID: 8063366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiplatelet therapies for the treatment of cardiovascular disease.
    Michelson AD
    Nat Rev Drug Discov; 2010 Feb; 9(2):154-69. PubMed ID: 20118963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet biology and functions: new concepts and clinical perspectives.
    van der Meijden PEJ; Heemskerk JWM
    Nat Rev Cardiol; 2019 Mar; 16(3):166-179. PubMed ID: 30429532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perspective on multi-target antiplatelet therapies: high content phenotypic screening as an unbiased source of novel polypharmacological strategies.
    Landré V; Amelio I; Barlev NA; Knight RA; Lisitsa A; Melino G; Antonov AV
    Mini Rev Med Chem; 2015; 15(8):622-9. PubMed ID: 25930110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted drug therapy: the platelet side.
    Lhermusier T; Van Rothem J; Garcia C; Gratacap MP; Payrastre B
    Platelets; 2011; 22(7):479-84. PubMed ID: 21973091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Platelet Activation and Oxidative Stress in the Evolution of Myocardial Infarction.
    Fuentes E; Moore-Carrasco R; de Andrade Paes AM; Trostchansky A
    J Cardiovasc Pharmacol Ther; 2019 Nov; 24(6):509-520. PubMed ID: 31280622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelets and vascular risk: an option for treatment.
    Jagroop IA; Kakafika AI; Mikhailidis DP
    Curr Pharm Des; 2007; 13(16):1669-83. PubMed ID: 17584097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphotyrosine signaling in platelets: lessons for vascular thrombosis.
    Wee JL; Jackson DE
    Curr Drug Targets; 2006 Oct; 7(10):1265-73. PubMed ID: 17073587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Our expanding view of platelet functions and its clinical implications.
    Ombrello C; Block RC; Morrell CN
    J Cardiovasc Transl Res; 2010 Oct; 3(5):538-46. PubMed ID: 20661787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.